Difference between revisions of "Ixabepilone (Ixempra)"
(updated content) |
m (→References) |
||
| Line 13: | Line 13: | ||
*[http://chemocare.com/chemotherapy/drug-info/ixabepilone.aspx Ixabepilone (Ixempra) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/ixabepilone.aspx Ixabepilone (Ixempra) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/chemotherapy/drug-info/ixabepilone.aspx Ixabepilone (Ixempra) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/ixabepilone.aspx Ixabepilone (Ixempra) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/ixabepilone-patient-drug-information Ixabepilone (Ixempra) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/ixabepilone-patient-drug-information Ixabepilone (Ixempra) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/ixabepilone-patient-drug-information Ixabepilone (Ixempra) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/ixabepilone-patient-drug-information Ixabepilone (Ixempra) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | *10/16/2007: Initial FDA approval: | ||
| + | # In combination with capecitabine is indicated for the treatment of metastatic or locally advanced breast cancer in patients after failure of an anthracycline and a taxane | ||
| + | # As monotherapy is indicated for the treatment of metastatic or locally advanced breast cancer in patients after failure of an anthracycline, a taxane, and capecitabine | ||
| + | |||
| + | ==Also known as== | ||
| + | Precise Name: ixabepilone (RXCUI 337523) | ||
==References== | ==References== | ||
Revision as of 02:21, 29 October 2013
General information
Class/mechanism: Microtubule inhibitor; semi-synthetic analog of epothilone B. Ixabepilone binds to beta tubulin on microtubules, suppresses the dynamic instability of alpha beta II and alpha beta III, and disrupts normal microtubule dynamics. This results in arrest in the mitotic phase of the cell cycle and cell death.[1][2][3]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Ixabepilone (Ixempra) patient drug information[4]
- Ixabepilone (Ixempra) patient drug information (Chemocare)[5]
- Ixabepilone (Ixempra) patient drug information (UpToDate)[6]
History of changes in FDA indication
- 10/16/2007: Initial FDA approval:
- In combination with capecitabine is indicated for the treatment of metastatic or locally advanced breast cancer in patients after failure of an anthracycline and a taxane
- As monotherapy is indicated for the treatment of metastatic or locally advanced breast cancer in patients after failure of an anthracycline, a taxane, and capecitabine
Also known as
Precise Name: ixabepilone (RXCUI 337523)
References
- ↑ 1.0 1.1 Ixabepilone (Ixempra) package insert
- ↑ Ixabepilone (Ixempra) package insert (locally hosted backup)
- ↑ Ixempra manufacturer's site
- ↑ Ixabepilone (Ixempra) patient drug information
- ↑ Ixabepilone (Ixempra) patient drug information (Chemocare)
- ↑ Ixabepilone (Ixempra) patient drug information (UpToDate)